BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
BioStem Technologies (OTC: BSEM) has received a Notice of Allowance from the USPTO for its patent application covering sterile human placental allografts with slits, openings, and fenestrations. The patent (No. 12,144,831) will grant on November 19, 2024, marking the first patent granted for tabular fenestrated allografts. The technology features flaps that allow exudate escape while maintaining surface area, suitable for acute and chronic wound care. The company's IP portfolio now includes 42 issued patents and 27 pending applications. The product, utilizing BioStem's BioREtain® process, is under development and will follow the HCT/P regulatory pathway.
BioStem Technologies (OTC: BSEM) ha ricevuto un Avviso di Ammissibilità dall'USPTO per la sua domanda di brevetto che copre allograft placentari umani sterili con fessure, aperture e fenestrazioni. Il brevetto (N. 12,144,831) sarà concesso il 19 novembre 2024, segnando il primo brevetto concesso per allograft fenestrati tabulari. La tecnologia presenta lembi che consentono la fuoriuscita di essudato mantenendo l'area superficiale, adatta per la cura delle ferite acute e croniche. Il portafoglio di proprietà intellettuale dell'azienda ora include 42 brevetti rilasciati e 27 domande in corso. Il prodotto, che utilizza il processo BioREtain® di BioStem, è attualmente in fase di sviluppo e seguirà il percorso normativo HCT/P.
BioStem Technologies (OTC: BSEM) ha recibido un Aviso de Aprobación de la USPTO para su solicitud de patente que cubre aloinjertos placentarios humanos estériles con cortes, aberturas y fenestraciones. La patente (N.º 12,144,831) se concederá el 19 de noviembre de 2024, marcando la primera patente concedida para aloinjertos fenestrados tabulares. La tecnología cuenta con solapas que permiten la escape de exudado mientras mantienen el área superficial, adecuada para el cuidado de heridas agudas y crónicas. La cartera de propiedad intelectual de la empresa ahora incluye 42 patentes emitidas y 27 solicitudes pendientes. El producto, que utiliza el proceso BioREtain® de BioStem, se encuentra en desarrollo y seguirá la ruta regulatoria HCT/P.
BioStem Technologies (OTC: BSEM)는 슬릿, 개구부 및 천공이 있는 무균 인체 태반 동종 이식편을 다루는 특허 출원에 대해 USPTO로부터 허가 통지를 받았습니다. 이 특허(번호 12,144,831)는 2024년 11월 19일에 부여될 예정이며, 이는 표면에 구멍이 있는 동종 이식편에 대해 부여된 최초의 특허입니다. 이 기술은 배출물이 빠져 나갈 수 있도록 하면서 표면적을 유지하는 플랩을 특징으로 하며, 급성 및 만성 상처 치료에 적합합니다. 회사의 지적 재산 포트폴리오는 현재 42개의 발급된 특허와 27개의 대기 중인 신청서를 포함하고 있습니다. BioStem의 BioREtain® 프로세스를 활용한 이 제품은 개발 중이며 HCT/P 규제 경로를 따를 예정입니다.
BioStem Technologies (OTC: BSEM) a reçu un Avis d'Admission de l'USPTO pour sa demande de brevet couvrant des allogreffes placentaire humaines stériles avec des fentes, des ouvertures et des fenêtres. Le brevet (n° 12,144,831) sera accordé le 19 novembre 2024, marquant le premier brevet accordé pour les allogreffes fenestrées tabulaires. La technologie présente des volets qui permettent l'évacuation des exsudats tout en maintenant la surface, adaptée aux soins des plaies aiguës et chroniques. Le portefeuille de propriété intellectuelle de l'entreprise comprend désormais 42 brevets délivrés et 27 demandes en attente. Le produit, utilisant le processus BioREtain® de BioStem, est en cours de développement et suivra le parcours réglementaire HCT/P.
BioStem Technologies (OTC: BSEM) hat eine Zulassungsbenachrichtigung vom USPTO für seinen Patentantrag erhalten, der sterile humane Plazenta-Transplantate mit Schlitzen, Öffnungen und Fenestrierungen abdeckt. Das Patent (Nr. 12,144,831) wird am 19. November 2024 erteilt und markiert das erste Patent für tabellarische fenestrierte Transplantate. Die Technologie weist Flaps auf, die den Austrag von Exsudat ermöglichen, während sie die Oberfläche erhalten, geeignet für die Behandlung akuter und chronischer Wunden. Das IP-Portfolio des Unternehmens umfasst nun 42 erteilte Patente und 27 anhängige Anträge. Das Produkt, das das BioREtain®-Verfahren von BioStem verwendet, befindet sich in der Entwicklung und wird den HCT/P-regulatorischen Weg folgen.
- First patent granted in the fenestrated wound care market
- Unique technology with no competing fenestrated allografts offering similar benefits
- Strong IP portfolio with 42 issued patents and 27 pending applications
- Product is still under development and not commercially available
Company continues to advance its placental-derived product portfolio with the first patent granted in the fenestrated wound care market
POMPANO BEACH, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for BioStem’s patent application No. 18/591,883 for STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREON. The patent application will grant as U.S. Patent No. 12,144,831 on November 19, 2024.
This patent will be used in the development of novel placental allografts designed for advanced wound care using BioStem’s BioREtain® process, which preserves essential natural factors. The allografts using this technology will feature flaps that open to allow exudate to escape without sacrificing surface area, making them suitable for both acute and chronic wound settings. This technology is unique, as there are no other fenestrated allografts on the market that offer the same benefits.
Jason Matuszewski, Chief Executive Officer of BioStem, stated: “BioStem continues to drive innovation in the wound care space, and we are pleased to enhance our intellectual property portfolio with the issuance of this significant patent. This is the first and only patent granted for use in tabular fenestrated allografts, which will support our commercial efforts and expands our IP portfolio. With 27 patents pending and 42 issued, BioStem has a strong portfolio across the wound care landscape that will protect the company as we advance in the market.”
A product using this technology is under development and is currently not commercially available and will be introduced using the HCT/P regulatory pathway. Once developed, the new allografts could be used as a protective covering for exudating wounds across the acute or chronic setting.
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE, and follow us on Twitter and LinkedIn.
About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
For more information visit biostemtechnologies.com and follow us on Twitter and LinkedIn.
Forward-Looking Statements:
Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStemTechnologies
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
646-863-6893
FAQ
What is the new patent granted to BioStem Technologies (BSEM)?
How many patents does BioStem Technologies (BSEM) currently have?
When will BioStem's (BSEM) new fenestrated allograft product be available?
